Biologics Market Outlook, Growth, Analysis, Outlook and Forecast 2024-2032

According to IMARC Group latest report titled “Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on biologics market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market.

The global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032.

Get a Sample Copy of this Report: https://www.imarcgroup.com/biologics-market/requestsample

Factors Affecting the Growth of the Biologics Industry:   

• Advancements in Biotechnological Techniques:

Cutting-edge technologies, including recombinant DNA technology, monoclonal antibody production, and next-generation sequencing, have enhanced the efficiency, specificity, and scalability of biologics manufacturing. These innovations enable the creation of more effective and targeted therapies for a range of diseases, particularly those for which traditional small-molecule drugs are ineffective. Furthermore, continuous improvements in gene editing tools, such as CRISPR-Cas9, offer promising avenues for developing novel biologic treatments, including gene therapies that could potentially cure genetic disorders. As biotechnological techniques evolve, the capability to design and produce biologics with unprecedented precision and efficacy will continue to propel the sector's growth.  

• Increasing Prevalence of Chronic Diseases:

The global rise in chronic diseases, such as diabetes, cancer, and autoimmune disorders, is a pivotal driver for the biologics market. Biologics have shown superior efficacy and safety profiles in treating these complex conditions compared to conventional medications, leading to their increased adoption. As the world's population ages and lifestyle-related health issues proliferate, the demand for advanced therapeutic options escalates. Biologics, with their ability to target specific pathways and cells involved in disease processes, offer personalized treatment modalities that improve patient outcomes. This growing burden of chronic diseases worldwide necessitates continued investment in biologics research and development to meet the expanding need for innovative treatments.

• Regulatory Support and Fast-track Approvals:

Supportive regulatory frameworks and the provision of fast-track approval processes by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), significantly contribute to the growth of the biologics sector. These agencies have implemented pathways that expedite the review and approval of biologics that address unmet medical needs, particularly for serious or life-threatening conditions. Such regulatory mechanisms reduce the time and cost associated with bringing new biologics to market, encouraging pharmaceutical companies to invest in biologic drug development. Moreover, regulatory incentives, including extended patent life and market exclusivity for certain biologics, further motivate the industry to pursue novel biologic therapies, thereby driving innovation and expansion in this field.   

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi

Biologics Market Report Segmentation:  

By Source:

• Microbial
• Mammalian
• Others

The microbial source segment dominates the biologics market due to its cost-effectiveness, simpler scaling-up processes, and the extensive use of microbial systems in the production of a wide range of biopharmaceuticals.

By Product:

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi and Molecular Therapy
• Others

Monoclonal antibodies lead the product segment within the biologics market, attributed to their wide-ranging applications in the treatment of chronic diseases, such as cancer and autoimmune diseases, coupled with significant investments in R&D activities.

By Disease:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Oncology emerges as the largest segment by disease in the biologics market, driven by the rising global incidence of cancer and the growing demand for biologic therapeutics that offer targeted and efficient treatment options.

By Manufacturing:

• Outsourced
• In-House

The In-house manufacturing segment holds the largest share in the biologics market, reflecting pharmaceutical companies’ preference for controlling the quality, production timelines, and intellectual property associated with their biologic products.

Regional Insights:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

North America stands as the largest market for biologics, due to its advanced healthcare infrastructure, high healthcare spending, strong presence of leading biopharmaceutical companies, and supportive regulatory environment for biologic therapies.

Biologics Market Trends:   

The emergence and expansion of the biosimilars market is another crucial factor influencing the growth of biologics. Biosimilars are highly similar to approved biologic drugs, known as reference products, but are manufactured by different companies after the original product's patent expires. The introduction of biosimilars introduces competition, reduces healthcare costs, and increases the accessibility of biologic therapies to patients. As patents on many blockbuster biologics expire, the biosimilars market is poised for significant growth, offering opportunities for pharmaceutical companies to enter the biologics space. This competitive environment benefits patients and stimulates innovation in the development of next-generation biologics and manufacturing processes.

Key highlights of the report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163